Navigation Links
NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
Date:4/15/2009

on of Pediatric Infectious Diseases; and Vice- Chairman, Department of Pediatrics. Dr. Whitley has served on several editorial and advisory boards and is currently the Vice President and President Elect for the Infectious Disease Society of America. Since 1980 Dr. Whitley has served as the Project Director for NIAID's Collaborative Antiviral Study Group, a multi-center clinical trial network directed to conduct studies to evaluate novel antiviral therapies that target unmet medical needs.

    More information on each CAB member may be found on the company's web site.


    ABOUT NEXBIO

NexBio, Inc. is a privately held development-stage biopharmaceutical company located in San Diego. NexBio's mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases. DAS181 (Fludase(R)), a recombinant fusion protein, inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza, including potential pandemic strains, and parainfluenza viruses (which may cause serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic) from infecting the human body or from amplifying in infected individuals. Unlike current antiviral compounds and vaccines, DAS181 targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with the currently available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance. Furthermore, DAS181 has been shown effective against influenza that is resistant to Tamiflu(R). The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Viradin(TM), invented and developed by NexBio, is a
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NexBio to Present at 2009 Biotech Showcase
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
4. Gen-Probe Completes Acquisition of Tepnel Life Sciences
5. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
6. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
7. Atritech Completes $30 Million Financing
8. Roche Completes Tender Offer for Genentech
9. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
10. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
11. Sangart, Inc. Completes Series F Funding Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 Oxford Finance LLC ("Oxford"), a ... sciences and healthcare services companies, today announced the closing ... with Celula, Inc., a diagnostic testing company focused on ... patient care and improved outcomes.  Proceeds of the loan ... the commercialization of its products in the U.S. and ...
(Date:4/30/2015)... April 30, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that it will release ... 7, 2015 after the close of the U.S. financial ... webcast on Thursday, May 7, 2015 at 4:30 p.m. ... and recent corporate developments. For both "listen-only" ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health ... joined SureClinical’s executive team as Chief Financial Officer. ... executive with over 25 years in leadership roles ranging ... Ms. Morris joins SureClinical from Marrone Bio Innovations (MBI), ... of MBI from its founding in 2006 until 2011, ...
(Date:4/29/2015)... (TSX-V: BRM) ("Biorem" or "the Company") today announced its results for the ... year-end financial statements and MD&A have been filed on SEDAR ( www.sedar.com ... 2014 , 2013 Revenue 3,968 , 5,121 ... , 1,703 , 2,231 , 5,866 Operating  ... , 4,562 Ebitda* 92 , 418 , ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... and somehow survived where other traditional marketing tools and ... names must face harsher realities once again, all to ... e-commerce, Web sites are simply doomed. While billions of ... only clash into the billions of surfing customers and ...
... At the UW-Madison College of Engineering, Dean Paul Peercy ... todays engineering education includes what it takes to be ... University of Wisconsin System and the Wisconsin Technical College ... graduate more people with four-year baccalaureate degrees and ...
... last year, I alluded to the internationalization of biotechnology. I was ... 4,284 biotech companies in 25 countries, according to a May 2004 ... biotech industry has 622 publicly traded companies around the world. ... , , The industry employed more than 188,000 people around ...
Cached Biology Technology:The mysteries and the future of Web sites 2The mysteries and the future of Web sites 3The mysteries and the future of Web sites 4Wisconsin must produce more science-savvy students to remain competitive 2Wisconsin must produce more science-savvy students to remain competitive 3In Globalizing Biotech, Midwest Must Differentiate From Pack 2In Globalizing Biotech, Midwest Must Differentiate From Pack 3In Globalizing Biotech, Midwest Must Differentiate From Pack 4
(Date:4/21/2015)... -- High crime rate, increasing government ... control systems market in Saudi Arabia ... report by TechSci Research " Saudi Arabia Access Control Systems Market ... market in Saudi Arabia is ... systems market in the Kingdom is growing at a ...
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... for processing information about human and animal faces, both how ... Tel Aviv University research is exploring what makes this highly ... finding practical applications for that information. In her ... TAU,s Department of Psychology is trying to understand the mechanisms ...
... at the UK,s University of Warwick, and the University of ... particular GM crop in India produced massive benefits in the ... research led by Dr Arjunan Subramanian of WMG (Warwick Manufacturing ... of GM insect-resistant Bacillus thuringiensis toxin (Bt) cotton generated ...
... have identified the behaviour of the mutant protein ,huntingtin, ... targets to treat the disease, a University of Melbourne ... with no cure, characterized by a steady decline in ... cells. The cause of the disease has long baffled ...
Cached Biology News:Can't place that face? 2GM crop produces massive gains for women's employment in India 2Huntington's disease discovery provides new hope for treatment 2
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Biology Products: